Graticule Asia Macro Advisors’s Adaptive Biotechnologies ADPT Stock Holding History

Graticule Asia Macro Advisors’s Portfolio ADPT Stock Details ADPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-45,600	Closed	-$2.7M	–	183
2020 Q4	$2.7M	Sell	45,600 -33,750	-43%	-$1.74M	1.29%	24
2020 Q3	$3.86M	Buy	+79,350	New	+$3.34M	0.38%	44
2020 Q1	–	Sell	-215,827	Closed	-$6.46M	–	18
2019 Q4	$6.46M	Sell	215,827 -140,499	-39%	-$4.03M	3.25%	11
2019 Q3	$11M	Buy	356,326 +117,535	+49%	+$4.8M	0.86%	32
2019 Q2	$11.5M	Buy	+238,791	New	+$10.6M	0.62%	39

Other funds holding ADPT

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Graticule Asia Macro Advisors's ADPT Position: Q1 2021 in Review

Graticule Asia Macro Advisors sold out of Adaptive Biotechnologies (ADPT) in Q1 2021, closing a stake of 45,600 shares — an estimated $2.7M sold.

Graticule Asia Macro Advisors first reported a position in ADPT in Q2 2019 and held it in 5 quarters. The position peaked at $11.5M in Q2 2019. 248 funds tracked by Wall St. Rank hold ADPT as of Q1 2021.

Graticule Asia Macro Advisors reported no remaining Adaptive Biotechnologies position as of Q1 2021 after selling out during the quarter.
Graticule Asia Macro Advisors sold 45,600 Adaptive Biotechnologies shares in Q1 2021, an estimated $2.7M.
Graticule Asia Macro Advisors first reported a position in Adaptive Biotechnologies in Q2 2019 and held it in 5 quarters.
Graticule Asia Macro Advisors's Adaptive Biotechnologies position peaked at $11.5M in Q2 2019.
248 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q1 2021.

Based on Graticule Asia Macro Advisors's 13F filing for Q1 2021, filed 17 May 2021.